Trastuzumab Emtansine
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Trastuzumab Emtansine |
| DrugBank ID | DB05773 |
| Brand Names (EU) | Kadcyla |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.90% |
Approved Indication (EMA)
Early Breast Cancer (EBC) Kadcyla, as a single agent, is indicated for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy. Metastatic Breast Cancer (MBC) Kadcyla, as a single agent, is indicated for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | HER2 positive breast carcinoma | 99.90% | DL |
| 2 | progesterone-receptor positive breast cancer | 99.82% | DL |
| 3 | normal breast-like subtype of breast carcinoma | 99.82% | DL |
| 4 | progesterone-receptor negative breast cancer | 99.82% | DL |
| 5 | breast tumor luminal A or B | 99.81% | DL |
| 6 | synovium cancer | 97.50% | DL |
| 7 | tenosynovial giant cell tumor | 96.73% | DL |
| 8 | tenosynovial giant cell tumor, localized type | 96.17% | DL |
| 9 | malignant giant cell tumor | 96.05% | DL |
| 10 | human herpesvirus 8-related tumor | 95.54% | DL |
| 11 | ectomesenchymoma | 95.52% | DL |
| 12 | malignant cutaneous granular cell skin tumor | 95.47% | DL |
| 13 | benign neoplasm of tongue | 95.47% | DL |
| 14 | cervical neuroblastoma | 95.45% | DL |
| 15 | schwannoma of jugular foramen | 95.45% | DL |
| 16 | benign neoplasm of hypopharynx | 95.43% | DL |
| 17 | benign neoplasm of buccal mucosa | 95.42% | DL |
| 18 | jugular foramen meningioma | 95.40% | DL |
| 19 | neoplasm of major salivary gland | 95.38% | DL |
| 20 | kidney pelvis sarcomatoid transitional cell carcinoma | 95.37% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.